EGR1 and acute myeloid leukemia: Similarly, in the Beat-AML cohort, high BATF expression was also correlated with poor outcome (3-year OS: 35.71% vs. 63.16%, P < 0.001) (Figure 1E), while high expression of EGR1 was associated with good outcome (3-year OS: 66.67% vs. 39.66%, P < 0.001) (Figure 1F).